Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OS004
- Development stage
- Preclinical
- Lead developer
- OmniSpirant
- Modality
- Stem Cell Therapies → Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Inhalation
01
Overview
OS004 is a preclinical-stage therapeutic candidate being developed by OmniSpirant for the treatment of pulmonary fibrosis. It is based on the company's proprietary OmniSome platform, which utilizes bioengineered stem cell-derived extracellular vesicles (exosomes) designed for inhaled delivery. These exosomes are engineered to deliver therapeutic payloads directly to lung tissue to address the underlying pathology of fibrotic lung diseases. The specific molecular target or payload for OS004 has not been publicly disclosed, but the platform is generally designed to deliver regenerative or anti-fibrotic factors via nebulization.
Beyond the preview
Go deeper on OS004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OS004.